OKYO Stock Forecast & Price Target

OKYO Pharma Ltd has demonstrated positive progress in its clinical trials, particularly with Urcosimod and OK-101, both showing favorable safety and tolerability in Phase 2 trials for dry eye disease (DED). Statistically significant improvements in symptoms such as stinging, burning, and ocular pain suggest that these therapeutics could effectively address neuropathic corneal pain (NCP), which is a significant health concern. The company's focus on developing innovative solutions for inflammatory eye diseases and chronic pain positions it well within a niche market, bolstered by the promising efficacy profiles of its key drug candidates.

OKYO Pharma Ltd faces significant risks that could adversely affect its financial outlook, including the potential failure of its lead candidate, OK-101, in critical clinical trials and the inability to secure regulatory approval in the U.S. In the period ending September 30, 2024, the company reported a net loss of $2.7 million, translating to a loss of $0.08 per share, indicating ongoing financial challenges. Furthermore, uncertainties surrounding market size, competition, and the possibility of dilution further contribute to a negative outlook on the stock.